# OnCo record cardiomyopathy-surveillance-after-childhood-cancer (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/cardiomyopathy-surveillance-after-childhood-cancer/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "cardiomyopathy-surveillance-after-childhood-cancer" ;
  schema:name "Heart scans after anthracyclines or chest radiotherapy for cancer in childhood, adolescence or young adulthood"@en ;
  schema:alternateName "cardiomyopathy surveillance in childhood cancer survivors"@en, "IGHG cardiomyopathy surveillance"@en, "echocardiogram after doxorubicin in childhood"@en, "late effects heart screening"@en, "COG echocardiogram schedule"@en, "anthracycline cardiomyopathy screening in survivors"@en, "echo every 2 years or every 5 years after childhood cancer"@en ;
  schema:description "Some childhood cancer medicines, such as doxorubicin and daunorubicin, and radiotherapy that reached the heart can weaken the heart muscle years later, often with no symptoms at first. International guidance sorts survivors by dose: a heart ultrasound scan every 2 years after higher doses, every 5 years after middle doses, and none after low doses. Carrying on for life is thought reasonable."@en ;
  schema:url <https://onco.cc/protocols/cardiomyopathy-surveillance-after-childhood-cancer/> ;
  schema:dateModified "2026-11-17"^^xsd:date ;
  onco:related <https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/>, <https://onco.cc/protocols/long-term-follow-up-after-childhood-cancer/>, <https://onco.cc/protocols/breast-screening-after-chest-radiotherapy-at-a-young-age/>, <https://onco.cc/collections/ighg/>, <https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/daunorubicin/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/idarubicin/>, <https://onco.cc/drugs/mitoxantrone/>, <https://onco.cc/drugs/dexrazoxane/> ;
  onco:cancers <https://onco.cc/cancers/childhood-cancers/>, <https://onco.cc/cancers/aya-cancers/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/rejuv-paed-heart/>, <https://onco.cc/technologies/cardio-oncology/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/cardiotoxicity/>, <https://onco.cc/terms/anthracycline/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/> .
